Abstract
Background: Genetic thrombophilia work up performance is subject to debate because of the utility of the information it provides regarding prognosis of recurrence of venous thromboembolism (VTE) and guidance of duration of therapy with anticoagulation. Certain algorithms have been locally developed to guide decision making process to increase the yield of thrombophilia work up. These algorithms are not based on locally derived data. Data from the Eastern Mediterranean area (Lebanon) have shown high prevalence of thrombophilia mutations. Therefore the aim of this study was to describe the experience of a tertiary care center in thrombophilia work up among patients diagnosed with VTE.
Methods: A retrospective chart analysis of the cases diagnosed with pulmonary embolism or deep venous thrombosis with radiological confirmation.
Results: A total of 133 patients' charts were reviewed, 27 patients had thrombophilia work up performed, 56% had heterozygous MTHFR mutation, 44% were heterozygous for the Factor V Leiden mutation and 3.2% were found to have Factor II heterozygous mutations, and a total of 33.3% of patients had more than one genetic mutation. The common causes of provoked VTE were 59.53% malignancy, 22.64% post surgery, 12.98% bed ridden patients, and 4.85% oral contraceptive pills. Only 14% of patients with a malignancy who presented with VTE where receiving prophylactic heparin.
Discussion: Doubly heterozygous prothrombotic genetic mutations are commonly present among Eastern Mediterranean patients with VTE. A prospective study to determine the predictive (negative and positive) power of the currently followed algorithm for genetic thrombophilia work up remains of significant importance. Stressing the favorable role of VTE prophylaxis among patients suffering from malignancies remains a target for raising awareness among oncologists.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002;121(3):877–905.
Lopez JA, Kearon C, Lee AY. Deep venous thrombosis. Hematology (Am Soc Hematol Educ Program) 2004;439–456.
Caprini JA, Goldshteyn S, Glase CJ, Hathaway K. Thrombophilia testing in patients with venous thrombosis. Eur J Vasc Endovasc Surg 2005.
McColl MD, Ramsay JE, Trait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997;78:1183.
Friederich PW, Sanson B-J, Simioni P, et al. Frequency of pregnancy related venous thromboembolism in anticoagulant factor-deficient women: Implications for prophylaxis. Ann Intern Med 1996;125:955.
Heijboer H, Brandjes DP, Buller HR, et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep vein thrombosis. N Engl J Med 1990;323:1512.
Murin S, Marelich GP, Arroliga AC, Matthay RA. Hereditary thrombophilia and venous thromboembolism. Am J Respir Crit Care Med 1998;158:1369.
Mansilha A, Araujo F, Severo M, Sampaio SM, Toledo T, Albuquerque R. Genetic Polymorphisms and Risk of Recurrent Deep Venous Thrombosis in Young People: Prospective Cohort Study. Eur J Vasc Endovasc Surg 2005.
Almawi WY, Finan RR, Tamim H, Daccache JL, Irani-Hakime N. Differences in the frequency of the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene among the Lebanese population. Am J Hematol 2004;76(1):85–87.
Zalloua PA, Shbaklo H, Mourad YA, Koussa S, Taher A. Incidence of thromboembolic events in Lebanese thalassemia intermedia patients. Thromb Haemost 2003;89(4):767–768.
Taher A, Khalil I, Shamseddine A, El-Ahdab F, Bazarbachi A. High prevalence of Factor V Leiden mutation among healthy individuals and patients with deep venous thrombosis in Lebanon: is the eastern Mediterranean region the area of origin of this mutation? Thromb Haemost 2001;86(2):723–724.
Isma’eel H, Taher A, Alam S, Arnaout MS. Massive Pulmonary Embolism in a Lebanese patient doubly heterozygous for MTHFR and Factor V Leiden presenting with Syncope and treated with Tenecteplase. Journal of Thrombosis and Thrombolysis 2005 (In Press).
Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon 2005;51(2–3):70–78.
Nicolaides AN. Thrombophilia and venous thromboembolism. International Consensus Statement. Guidelines According to Scientific Evidence. Int Angiol 2005;24(1):1–26.
Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):401S–428S. Review. Erratum in: Chest 2005;127(1):416.
Goldhaber SZ, Tapson VF; DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004;93(2):259–62.
Gallus AS. Travel, venous thromboembolism, and thrombophilia. Semin Thromb Hemost 2005;31(1):90–96.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Isma’eel, H., Accaoui, R.E., Shamseddeen, W. et al. Genetic thrombophilia in patients with VTE in eastern mediterranean located tertiary care center; is it time to change the algorithm for thrombophilia work up decision making?. J Thromb Thrombolysis 21, 267–270 (2006). https://doi.org/10.1007/s11239-006-5537-1
Issue Date:
DOI: https://doi.org/10.1007/s11239-006-5537-1